

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATIENT TRIAL AND APPEAL BOARD

AMNEAL PHARMACEUTICALS LLC, PAR PHARMACEUTICALS, INC. and
WOCKHARDT BIO AG,

Petitioners,

v.

JAZZ PHARMACEUTICALS, INC.,

Patent Owner

Case IPR2015-00554

Patent 7,668,730

Oral deposition of DR. JOSEPH DIPIRO, taken at the
offices of Quinn Emanuel Urquhart & Sullivan, LLP, 51
Madison Avenue, 22nd Floor, New York, New York 10010, on
Wednesday, February 3, 2016, at 9:35 a.m., before Anthony
Armstrong, a Realtime Systems Administrator, Certified
Realtime Reporter, Certified Court Reporter and Notary
Public of the State of New York.

DIGITAL EVIDENCE GROUP
1730 M Street NW, Suite 812
Washington, DC 20036
(202) 232-0646

1 APPEARANCES:
 2
 3 MADDOX EDWARDS, PLLC
 4 1900 K Street NW, Suite 725
 5 Washington, DC 20006
 6 BY: MATTHEW C. RUEDY, ESQ.,
 7 (202)830-0779
 8 mruedy@meiplaw.com
 9 Attorneys for Amneal Pharmaceuticals
 10
 11 ARENT FOX, LLP
 12 1717 K Street, NW
 13 Washington, DC 20038
 14 BY: RICHARD J. BERMAN, ESQ.,
 15 (202)857-6000
 16 richard.berman@arentfox.com
 17 Attorneys for Par Pharmaceuticals
 18
 19 QUINN EMANUEL URQUHART & SULLIVAN, LLP
 20 51 Madison Avenue, 22nd Floor
 21 New York, New York 10010
 22 BY: ERIC STOPS, ESQ.,
 (212)849-7561
 ericstops@quinnemanuel.com
 BY: EVANGELINE SHIH, ESQ.,
 (212)849-7000
 evangelinesh@quinnemanuel.com
 Attorneys for Jazz Pharmaceuticals

Page 2

1 JOSEPH DIPIRO, Pharma.D., a witness, having
 2 first been duly sworn, testified as follows:
 3 MR. RUEDY: For the record, we're
 4 here today for a deposition in a series of
 5 enter parties' review IPR Nos. 2015-00545,
 6 546, 547, 548, 551, 554, and the related
 7 joined cases. Good morning.
 8 MR. STOPS: Shall we do
 9 introductions?
 10 MR. RUEDY: Sure.
 11 MR. STOPS: This is Eric Stops from
 12 Quinn Emanuel for the patent owner Jazz
 13 Pharmaceuticals and the witness. With me is
 14 Evangeline Shih, also from Quinn Emanuel.
 15 MR. RUEDY: Matthew Ruedy from Maddox
 16 Edwards representing Amneal Pharmaceuticals.
 17 MR. BERMAN: Rich Berman from Arent
 18 Fox representing Par Pharmaceutical.
 19
 20 (Testimony continued on next
 21 page.)
 22

Page 4

1 INDEX
 2
 3 WITNESS PAGE
 4 DR. JOSEPH DIPIRO
 5 By Mr. Ruedy 4
 6
 7 EXHIBITS
 8 NUMBER DESCRIPTION PAGE
 9 (There were no exhibits marked)
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22

Page 3

1 DIRECT EXAMINATION
 2 BY MR. RUEDY:
 3 Q. Good morning.
 4 A. Good morning.
 5 Q. Could you please state your name and
 6 address for the record.
 7 A. Joseph T. DiPiro. And my residence
 8 is at 3991 Reads Landing Circle, Richmond,
 9 Virginia.
 10 Q. I just want to go over a few ground
 11 rules before we get started with the deposition.
 12 I'm going to ask you a series of
 13 questions. When you answer, please do so verbally
 14 for the record, as our court reporter here will be
 15 transcribing your verbal answers. So no head
 16 nods, no yes, no shaking of the head, if that
 17 works.
 18 A. I may slip from time to time, but I
 19 will do my best. I would not mind a reminder.
 20 Q. Sure. If you don't understand one of
 21 my questions, please ask for clarification. If
 22 you do answer, that means that you understood the

Page 5

<p>1 question. Okay?</p> <p>2 A. Yes.</p> <p>3 Q. And if you need a break at any time,</p> <p>4 just please let me know. All I ask is if there</p> <p>5 is a question pending, that the question be</p> <p>6 answered prior to us taking a break.</p> <p>7 A. Sure.</p> <p>8 Q. Is there any reason that you cannot</p> <p>9 give full and complete answers today?</p> <p>10 A. No.</p> <p>11 Q. Have you ever been deposed before?</p> <p>12 A. Yes.</p> <p>13 Q. How many times?</p> <p>14 A. Twice.</p> <p>15 Q. What did each of those cases involve?</p> <p>16 A. The most recent was about three years</p> <p>17 ago, and was a personal property dispute related</p> <p>18 to my family.</p> <p>19 Q. And the second?</p> <p>20 A. Was a -- approximately 10 years ago,</p> <p>21 with some followup in a year or two after, a</p> <p>22 patent case that I was working with Jones Day</p> <p style="text-align: right;">Page 6</p>	<p>1 was?</p> <p>2 A. The one that I referred to first</p> <p>3 occurred about 10 years ago was Skelaxin.</p> <p>4 Q. And then the other one?</p> <p>5 A. I don't recall.</p> <p>6 Q. Was either one of those cases Elan v.</p> <p>7 Corepharma?</p> <p>8 A. That could be. That sounds right.</p> <p>9 Q. And was that the Skelaxin case?</p> <p>10 A. I believe so. Again, it's -- I have</p> <p>11 not refreshed my memory on this, so it's going</p> <p>12 back 10 years.</p> <p>13 Q. And then the second case, was that</p> <p>14 King Pharma versus Eon?</p> <p>15 A. That sounds right, yes, to the best</p> <p>16 of my memory.</p> <p>17 Q. And Quinn Emanuel was your counsel</p> <p>18 for that case, correct?</p> <p>19 MR. STOPS: Objection. Foundation.</p> <p>20 A. I was working with lawyers at Jones</p> <p>21 Day.</p> <p>22 Q. Okay. How many cases have you worked</p> <p style="text-align: right;">Page 8</p>
<p>1 from.</p> <p>2 Q. And do you remember the name of that</p> <p>3 case?</p> <p>4 A. I remember some points about it, the</p> <p>5 particular drug involved in the patent, and I</p> <p>6 probably couldn't recall all the parties involved</p> <p>7 in the litigation.</p> <p>8 Q. But from your general recollection,</p> <p>9 what was the drug involved?</p> <p>10 A. Skelaxin.</p> <p>11 Q. How many patent cases have you been</p> <p>12 involved with?</p> <p>13 A. I know -- so prior to that I was</p> <p>14 involved in another report without deposition</p> <p>15 with Jones Day. It may have been a couple of</p> <p>16 years earlier. And between that experience and</p> <p>17 the first one that I related to, I'm not clear</p> <p>18 how many patents were involved there. To my way</p> <p>19 of thinking, there were two cases that I don't</p> <p>20 recall that they were related.</p> <p>21 Q. Okay. And in that second case with</p> <p>22 Jones Day, do you recall what the drug at issue</p> <p style="text-align: right;">Page 7</p>	<p>1 on -- how many patent cases have you worked with</p> <p>2 Jones Day on?</p> <p>3 A. So the only ones that I was involved</p> <p>4 with -- so 10 years ago one involved report and</p> <p>5 deposition with Skelaxin. Within the next year</p> <p>6 or two, there were followup reports; no further</p> <p>7 depositions. And then a couple of years prior to</p> <p>8 that, a report with Jones Day. And those are the</p> <p>9 only ones related to patents that I have been</p> <p>10 involved with.</p> <p>11 Q. Have you ever testified in a district</p> <p>12 court case?</p> <p>13 A. I once provided testimony for a</p> <p>14 malpractice case. I'm not sure what the</p> <p>15 jurisdiction was. And this would have been</p> <p>16 almost a decade ago.</p> <p>17 Q. But not a patent case?</p> <p>18 A. Not a patent case.</p> <p>19 Q. Are you represented by counsel today?</p> <p>20 A. I'm working in conjunction with the</p> <p>21 legal counsel for Quinn Emanuel.</p> <p>22 Q. What did you do to prepare for</p> <p style="text-align: right;">Page 9</p>

1 today's deposition?
 2 A. I worked in conjunction with legal
 3 counsel to review the relevant documents that are
 4 cited in my statement and prepare the -- my
 5 statement.
 6 Q. So as far as preparing for today's
 7 deposition, did you meet with counsel?
 8 A. Yes.
 9 Q. Who did you meet with?
 10 A. With the counsel that you see here,
 11 and Frank Calvosa.
 12 Q. How many days did you meet?
 13 A. Two days.
 14 Q. And you mentioned that you reviewed
 15 documents to prepare for your deposition.
 16 What did you review specifically?
 17 A. They're all stated in my -- and
 18 listed in my statement. It includes the ACA
 19 materials and the patent documents and the
 20 declaration of Dr. Valuck among those that I
 21 reviewed.
 22 Q. Okay. So referring to your expert

Page 10

1 declarations, you submitted six of them for six
 2 different inter partes reviews -- proceedings,
 3 correct?
 4 A. Yes.
 5 Q. I'm just going to shortcut and say
 6 IPR, if that's okay with you, for inter partes
 7 review.
 8 A. I know we have used that term, but
 9 remind me what that acronym --
 10 Q. Inter partes review?
 11 A. Yes.
 12 Q. I'm just referring to the general
 13 type of case that we're here for today, if that's
 14 okay with your understanding.
 15 A. Right. I don't have a working
 16 definition of that term, but I thank you for the
 17 explanation.
 18 Q. Okay. It just saves me from having
 19 to repeat inter partes review.
 20 A. Sure.
 21 Q. Each of these IPRs were filed either
 22 by Par Pharmaceutical or Amneal Pharmaceuticals,

Page 11

1 correct?
 2 A. I'm not clear which documents you're
 3 referring to.
 4 Q. I'm just referring to the
 5 petitioner's on the IPRs. I'll submit to you
 6 that each of these IPRs were filed initially by
 7 Par Pharmaceutical and or Amneal pharmaceuticals
 8 LLC.
 9 Just to make things easier, I'm
 10 referring to the entities that filed the IPRs as
 11 the petitioners, if that's okay with you.
 12 A. Well, you know, I don't have an
 13 opinion about that because I'm not familiar with
 14 the legal process, who files what.
 15 If you're asking me is that the way it
 16 happened --
 17 Q. I'm just asking you so that we have
 18 an understanding of what I am referring to when I
 19 say petitioner. I'm referring to the parties
 20 that filed the IPRs in front of the patent
 21 office. That's all.
 22 A. Okay. Yes.

Page 12

1 Q. So the six different patents in these
 2 IPRs are owned by Jazz Pharmaceuticals, right?
 3 A. That's my understanding.
 4 Q. And these six patents generally deal
 5 with restricted drug distribution systems, right?
 6 A. Yes.
 7 Q. Are you okay with that general
 8 description? I'm not going to hold you to it
 9 necessarily, but I just want something that we
 10 can agree on that the patents generally cover.
 11 A. Yes.
 12 Q. Have you read each of the six
 13 patents?
 14 A. Yes.
 15 Q. Did you read the entirety of each of
 16 them?
 17 A. Yes. And I recognize that much of
 18 that is the same or very similar from one to the
 19 next.
 20 Q. When were you first contacted about
 21 this case?
 22 A. I don't recall the exact date, but it

Page 13

1 may have been in October -- in the middle of the
 2 fall this past year, 2015.
 3 Q. Who contacted you?
 4 A. Would have been Angela Chi.
 5 Q. When you were contacted about this
 6 case, what were you asked to do?
 7 MR. STOPS: Objection, to the extent
 8 the question calls for attorney/client
 9 communications. Maybe there's a way you can
 10 ask that question without getting to --
 11 MR. RUEDY: I'm not looking for
 12 protected information.
 13 BY MR. RUEDY:
 14 Q. I'm just looking in general what were
 15 you asked to do.
 16 MR. STOPS: That question still may
 17 call for attorney/client communications.
 18 You can answer generally to the extent
 19 you can without revealing attorney/client
 20 compilations.
 21 THE WITNESS: Repeat the question.
 22 MR. RUEDY: If you can read it back,

Page 14

1 Q. The subject matter of the patents,
 2 the restricted drug distribution system.
 3 A. Well, I relied on what was supplied
 4 by counsel in terms of the materials that are
 5 cited in my report. I did not obtain those
 6 independently.
 7 Q. So my question is, did you do any
 8 other research beyond the materials provided by
 9 counsel?
 10 A. Minimal.
 11 Q. What do you mean by minimal?
 12 A. I spent a small amount of time
 13 reading about Xyrem and the manufacturers'
 14 restricted distribution system, the material that
 15 was on their website.
 16 Q. Was all the materials that you
 17 reviewed on the Xyrem website?
 18 MR. STOPS: Objection, form.
 19 A. I'm trying to recall what I looked
 20 at. I really didn't spend a minimal amount of
 21 time outside the documents that were provided,
 22 and so I do recall specifically that I looked up

Page 16

1 please.
 2 (The record was read.)
 3 *****
 4 A. Well, I was asked if I would be
 5 willing to provide an opinion about the case and
 6 the issues at hand.
 7 BY MR. RUEDY:
 8 Q. After you were contacted, were you
 9 asked to do any research for this case?
 10 A. So it depends on what you mean by
 11 research. I would say yes, in that I then went
 12 through the relevant documents in the case to
 13 gain a better understanding of all the issues.
 14 Q. Did you do your own independent
 15 literature search?
 16 A. I do literature searches for a lot of
 17 things all the time. So specifically for what
 18 purpose?
 19 Q. I'm just asking generally if -- once
 20 you were contacted about this case whether you
 21 chose to research the subject matter on your own?
 22 A. What subject matter?

Page 15

1 about Xyrem to become more familiar with it and
 2 redistricted distribution system. I don't recall
 3 spending time doing other types of research at
 4 that point time. You've directed me to this
 5 initial contact and that time period.
 6 Q. When you say a minimal amount of
 7 time, can you quantify that at all?
 8 A. Probably 30 minutes.
 9 Q. Prior to being contacted in this
 10 case, had you heard of Xyrem previously?
 11 A. I had heard of it, yes.
 12 Q. In what capacity?
 13 A. I don't recall from what source the
 14 information came from. It may have been one of a
 15 number of news feeds that we routinely receive.
 16 So I don't recall where it came from, but I was
 17 aware of the name.
 18 Q. Do you recall when you first heard of
 19 Xyrem?
 20 A. No.
 21 Q. Prior to being contacted in this
 22 case, had you heard of GHP?

Page 17

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.